tbuckley/cabot-search huggingface dataset:
Catheter Ablation of Atypical Atrioventricular Nodal Reentrant Tachycardia
Authors: Demosthenes G. Katritsis, Joseph E. Marine, Fernando M. Contreras, Akira Fujii, Rakesh Latchamsetty, Konstantinos C. Siontis, George D. Katritsis, Theodoros Zografos, Roy M. John, Lawrence M. Epstein, Gregory F. Michaud, Elad Anter, Ali Sepahpour, Edward Rowland, Alfred E. Buxton, Hugh Calkins, Fred Morady, William G. Stevenson, Mark E. Josephson
Journal: Circulation (2016)

Because of its low prevalence, data on atypical atrioventricular nodal reentrant tachycardia (AVNRT) are scarce, and the optimal ablation method has not been established. Our study aimed at assessing the efficacy and safety of conventional slow pathway ablation, as applied for typical cases, in atypical AVNRT.We studied 2079 patients with AVNRT subjected to slow pathway ablation. In 113 patients, mean age 48.5±18.1 years, 68 female, atypical AVNRT or coexistent atypical and typical AVNRT without other concomitant arrhythmia was diagnosed. Ablation data and outcomes were compared with a group of age- and sex-matched control patients with typical AVNRT.Fluoroscopy and radiofrequency current delivery times were not different in the atypical and typical groups, 20.3±12.2 versus 20.8±12.9 minutes (P=0.730) and 5.9±5.0 versus 5.5±4.5 minutes (P=0.650), respectively. Slow pathway ablation was accomplished from the right septum in 110 patients, and from the left septum in 3 patients, in the atypical group. There was no need for additional ablation lesions at other anatomic sites, and no cases of atrioventricular block were encountered. Recurrence rates of the arrhythmia were 5.6% in the atypical (6/108 patients) and 1.8% in the typical (2/111 patients) groups in the next 3 months following ablation (P=0.167).Conventional ablation at the anatomic area of the slow pathway is the therapy of choice for symptomatic AVNRT, regardless of whether the typical or atypical form is present.
Protein kinase Cθ controls type 2 innate lymphoid cell and TH2 responses to house dust mite allergen
Authors: Fahima Madouri, Pauline Chenuet, Chloé Beuraud, Louis Fauconnier, Tiffany Marchiol, Nathalie Rouxel, Aurélie Ledru, Margaux Gallerand, Vincent Lombardi, Laurent Mascarell, Quentin Marquant, Lionel Apetoh, François Erard, Marc Le Bert, Fabrice Trovero, Valérie F.J. Quesniaux, Bernhard Ryffel, Dieudonnée Togbe
Journal: Journal of Allergy and Clinical Immunology (2016)
Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients
Authors: Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann
Journal: Blood (2015)
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients
Authors: Kate Stringaris, David Marin, A. John Barrett, Robert Hills, Catherine Sobieski, Kai Cao, Jerome G. Saltarrelli, May Daher, Hila Shaim, Nathaniel Smith, David Linch, Rosemary Gale, Christopher Allen, Takuya Sekine, Rohtesh Mehta, Richard Champlin, Elizabeth J. Shpall, Hagop Kantarjian, Guillermo Garcia-Manero, Katayoun Rezvani
Journal: Blood (2016)
Construction and Analysis of Functional Networks in the Gut Microbiome of Type 2 Diabetes Patients
Authors: Lianshuo Li, Zicheng Wang, Peng He, Shining Ma, Jie Du, Rui Jiang
Journal: Genomics Proteomics & Bioinformatics (2016)

Although networks of microbial species have been widely used in the analysis of 16S rRNA sequencing data of a microbiome, the construction and analysis of a complete microbial gene network are in general problematic because of the large number of microbial genes in metagenomics studies. To overcome this limitation, we propose to map microbial genes to functional units, including KEGG orthologous groups and the evolutionary genealogy of genes: Non-supervised Orthologous Groups (eggNOG) orthologous groups, to enable the construction and analysis of a microbial functional network. We devised two statistical methods to infer pairwise relationships between microbial functional units based on a deep sequencing dataset of gut microbiome from type 2 diabetes (T2D) patients as well as healthy controls. Networks containing such functional units and their significant interactions were constructed subsequently. We conducted a variety of analyses of global properties, local properties, and functional modules in the resulting functional networks. Our data indicate that besides the observations consistent with the current knowledge, this study provides novel biological insights into the gut microbiome associated with T2D.
Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction
Authors: John W. Pickering, Jaimi H. Greenslade, Louise Cullen, Dylan Flaws, William Parsonage, Sally Aldous, Peter George, Andrew Worster, Peter A. Kavsak, Martin P. Than
Journal: Circulation (2016)

Background: The new European Society of Cardiology guidelines to rule-in and rule-out acute myocardial infarction (AMI) in the emergency department include a rapid assessment algorithm based on high-sensitivity cardiac troponin and sampling at 0 and 1 hour. Emergency department physicians require high sensitivity to confidently rule-out AMI, whereas cardiologists aim to minimize false-positive results. Methods: High-sensitivity troponin I and T assays were used to measure troponin concentrations in patients presenting with chest-pain symptoms and being investigated for possible acute coronary syndrome at hospitals in New Zealand, Australia, and Canada. AMI outcomes were independently adjudicated by at least 2 physicians. The European Society of Cardiology algorithm performance with each assay was assessed by the sensitivity and proportion with AMI ruled out and the positive predictive value and proportion ruled-in. Results: There were 2222 patients with serial high-sensitivity troponin T and high-sensitivity troponin I measurements. The high-sensitivity troponin T algorithm ruled out 1425 (64.1%) with a sensitivity of 97.1% (95% confidence interval [CI], 94.0%–98.8%) and ruled-in 292 (13.1%) with a positive predictive value of 63.4% (95% CI, 57.5%–68.9%). The high-sensitivity troponin I algorithm ruled out 1205 (54.2%) with a sensitivity of 98.8% (95% CI, 96.4%–99.7%)) and ruled-in 310 (14.0%) with a positive predictive value of 68.1% (95% CI, 62.6%–73.2%). Conclusions: The sensitivity of the European Society of Cardiology rapid assessment 0-/1-hour algorithm to rule-out AMI with high-sensitivity troponin may be insufficient for some emergency department physicians to confidently send patients home. These algorithms may prove useful to identify patients requiring expedited management. However, the positive predictive value was modest for both algorithms.
Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution
Authors: Xenia Cabagnols, Jean-Philippe Defour, Valérie Ugo, Jean Christophe Ianotto, Pascal Mossuz, Julie Mondet, Francois Girodon, Alexandre Ji-Hye, Olivier Mansier, Jean François Viallard, Eric Lippert, Anne Murati, MJ Mozziconacci, Ollivier Legrand, Pascale Saussoy, Marie-Christianne Vekemans, Laurent Knoops, Florence Pasquier, Vincent Ribrag, Eric Solary, Isabelle Plo, Stefan N. Constantinescu, Nicole Casadevall, William Vainchenker, Christophe Marzac, Olivier Bluteau
Journal: Blood (2014)
Behavioral Health Workforce and Private Sector Solutions to Addressing Veterans’ Access to Care Issues
Authors: Grant R. Martsolf, Andrada Tomoaia-Cotisel, Terri Tanielian
Journal: JAMA Psychiatry (2016)

This Viewpoint reports on the range of policy solutions proposed to address concerns about whether the Veterans Health Administration can adequately address the challenges in meeting the need for veterans’ care, especially in behavioral health.
Mortality from prostate cancer (PC) in Pennsylvania(PA) in civilian versus Veterans Administration (VA) populations
Authors: G. M. Lubiniecki, Z. Chen, S. Thompson, K. M. Algazy
Journal: Journal of Clinical Oncology (2004)

4768 Background/Methods: The PA Cancer Registry was used to identify all cases of PC diagnosed in PA from 1996–2000. The hospital code of diagnosis(dx) distinguished VA from civilian hospitals. Registry data were used to compare age at dx, ethnicity, stage of dx, year of death, and cause of death between the VA and civilian populations. All of these factors and treatment at a VA facility were included in a multivariate analysis to assess their impact on PC-specific mortality. A case was included in the analysis if data for all variables were present and they were from the years 1996 to 2000. Results: From 1996 to 2000, 49,779 cases of PC were diagnosed. 36,191 patients met the inclusion criteria, 35,186 cases in the civilian population and 1,023 cases in the VA population. Ethnicity data between the civilian and VA populations were as follows: Caucasian 89.9% vs. 67.5% and African-American 9.6% vs. 31.6%. The median ages of dx were 68 and 69 years in the civilian and VA populations, respectively. The stages of disease at dx were equivalent between the civilian and VA populations (local or in situ disease 87.3% vs. 89.2%, locally advanced 9.6% vs. 6.7%, metastatic 3.1% vs. 4.0%). PC-specific mortality was higher in the VA population (1.8% vs. 2.6%). In the multivariate analysis, when controlling for all variables, VA patients were 1.3 times as likely to die from PC as civilians. Although this result is not statistically significant (p=0.16), an analysis including more detailed information regarding the time of death might be statistically significant because the analysis would have more power. This analysis is being pursued. Interestingly, age at dx was a statistically significant (p<0.01) independent predictor of mortality. Patients had a 1.1 fold higher mortality than patients diagnosed one year younger. Conclusions: Mortality from PC is equivalent between the VA and civilian populations in PA. The increased risk of death from PC found in this analysis in older men diagnosed in PA contradicts other multivariate analyses. In this analysis, age at dx may be a surrogate marker for other factors, like hemoglobin, that have been found to impact survival. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Philadelphia VA-Heme/Onc Division Head, Veterans Administration Veterans Administration
High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience.
Authors: Maria Vogiatzi, Eric Macklin, Robert Schneider, Joseph Lane, Nancy Olivieri, Melanie Kirby, Angela Cheung, Elliott Vichinsky, Ellen Fung, Alan Cohen, Janet Kwiatkowski, Virginia Stallings, Ingrid Holm, Ellis Neufeld, Patricia J. Giardina
Journal: Blood (2005)
GW26-e0742 Assessment of the left atrial appendage structure and function of the non-valvular atrial fibrillation by real-time three-dimensional transesophageal echocardiography
Authors: Zhongxiu Chen, Wenjuan Bai, Hui Wang, Chen Li, Wei Cheng, Hong Tang, Li Rao
Journal: Journal of the American College of Cardiology (2015)
Efficacy and tolerability of rituximab-based chemotherapy in CD20-positive non-Hodgkin lymphoma (NHL)
Authors: A. Polakiewicz-Gilowska, I. Cedrych, E. Nowara
Journal: Journal of Clinical Oncology (2008)

19542 Background: Introduction of rituximab to the treatment of CD20-positive NHL became a cornerstone in the modern management of this entity. The purpose of this retrospective study was to evaluate the efficacy and tolerability of rituximab combined with chemotherapy, based on the FDA/EMEA treatment approval in particular CD20-positive NHL. Methods: Between 2002- 2006 56 patients (34 women and 21 men), median age 51 years (range 18–72) with newly diagnosed B-cell NHL were treated in our department.43 patients (76%) suffered from diffuse large B-cell lymphoma (DLBCL),10 (18%) were diagnosed with follicular lymphoma, 3 (6%) had other indolent lymphoma histology. According to the IPI score 53,5% had low risk disease, 28,5% low-intermediate, 16% high- intermediate, 1 patient had high risk disease. In 51 patients rituximab was added to CHOP regimen and in 5 patients to COP regimen. The median number of rituximab doses was 6. Results: Overall response rate (ORR) was 83,6% with complete regression (CR) rate 64%. Stable disease (SD) occurred in 4,1% of cases, and disease progression (PD) was observed in 11,6% of patients. In DLBCL patients CR was achieved in 27 (62,7%) patients, partial regression (PR) in 9 (20,9%) and SD in 2 (4,6%) patients. 5 patients had progression. With median follow-up of period 34 months 2-year progression-free and overall survivals were 75% and 81% respectively. In Cox proportional-hazards model only IPI > 2 score had negative impact on overall survival (p=0,047). Toxicity was mild, the most common adverse events (grades 1–2) were neutropenia (7%), stomatitis (4,3%),peripheral neuropathy (4,3%), there were only 3 infectious complications and 2 cardiovascular incidents, no grade 4 toxicity was observed. Conclusions: Rituximab-based chemotherapy is effective and well-tolerated treatment modality for CD20 positive non-Hodgkin lymphoma patients. However, patients with high-intermediate and high IPI score might not benefit enough from such treatment, and optimal therapy for these cases needs to be determined. No significant financial relationships to disclose.
GW26-e2423 The role of mutant Plzf in metabolic and hemodynamic disturbances in spontaneously hypertensive rats
Authors: Petr Mlejnek, Vladimir Landa, Vaclav Zidek, Jan Silhavy, Miroslava Simakova, Michal Pravenec, Frantisek Liska, Ludmila Kazdova, Zsuzsanna Izsvak, Massimiliano Mancini
Journal: Journal of the American College of Cardiology (2015)
Probing the Impact of AMD3100/GCSF Mobilization on the Peripheral Blood T Cell Content Using a Rhesus Macaque Model: Increased Proportions of FoxP3+/CD4+ T Cells Occur After Mobilization and Leukapheresis
Authors: Leslie Kean, Sharon Sen, Mark E Metzger, Aylin Bonifacino, Karnail Singh, Robert E Donahue
Journal: Blood (2010)
<i>Notes from the Field</i>: Outbreak of Zika Virus Disease — American Samoa, 2016
Authors: Jessica M. Healy, M. Catherine Burgess, Tai-Ho Chen, W. Thane Hancock, Karrie-Ann E. Toews, Magele Scott Anesi, Ray T. Tulafono, Mary Aseta Mataia, Benjamin Sili, Jacqueline Solaita, A Christian Whelen, Rebecca Sciulli, Remedios B. Gose, Vasiti Uluiviti, Morgan Hennessey, Fara Utu, Motusa Tuileama Nua, Marc Fischer
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

During December 2015-January 2016, the American Samoa Department of Health (ASDoH) detected through surveillance an increase in the number of cases of acute febrile rash illness. Concurrently, a case of laboratory-confirmed Zika virus infection, a mosquito-borne flavivirus infection documented to cause microcephaly and other severe brain defects in some infants born to women infected during pregnancy (1,2) was reported in a traveler returning to New Zealand from American Samoa. In the absence of local laboratory capacity to test for Zika virus, ASDoH initiated arboviral disease control measures, including public education and vector source reduction campaigns. On February 1, CDC staff members were deployed to American Samoa to assist ASDoH with testing and surveillance efforts.
A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.
Authors: Jorge Cortes, Hagop M. Kantarjian, Michele Baccarani, Tim H. Brummendorf, Delong Liu, Gert Ossenkoppele, Angela D.G. Volkert, Becker Hewes, Laurence Moore, Charles Zacharchuk, Carlo Gambacorti
Journal: Blood (2006)
Abstract B05: N-Myc downstream regulated gene 2 is a novel regulator of lipid metabolism and ubiquitin-proteasome system in cancer
Authors: Libo Yao, Xia Li, Xiping Liu, Yi Ru, Mei Zhang
Journal: Cancer Research (2016)

Abstract Background and Aims: Oncogene activation and tumor suppressor gene inactivation alter multiple intracellular signaling pathways that affect metabolism of cancer cells. NDRG2 (N-Myc downstream regulated gene 2) is a newly identified tumor suppressor gene in our lab and others. We reported previously that NDRG2 functions as an essential regulator in glycolysis and glutaminolysis via repression of c-MYC, and acts as a suppressor of carcinogenesis through coordinately targeting glucose and glutamine transporter, multiple catalytic enzymes involved in glycolysis and glutaminolysis, which fuels the bioenergy and biomaterials needed for cancer proliferation and progress. Our recent studies showed that NDRG2 is involved in cell apoptosis or survival when the cells are challenged by various stress factors such as hypoxia and lipotoxicity. However, whether NDRG2 is implicated in lipid metabolism and other cellular process is unknown. Methods: We explored the role of NDRG2 in lipid metabolism by using Oil red staining of the liver tissues from Ndrg2 mouse v.s. wild-type counterpart. We also examined the effect of Ndrg2 on the transcription of the proteasome subunits by RT-PCR, its effect on the proteasome activity by protease activity assay, as well as Nrf1 relevance in such regulation, through using the liver tissues of mouse and NDRG2-overxepressing HepG2 cells. Results: Ndrg2 mice exhibited lipid accumulation in liver compared with the wild-type counterpart. Besides, the proteasome genes transcription were upregulated in Ndrg2 liver tissue but downregulated in NDRG2-overexpressing HepG2 cells. Moreover, NDRG2-overexpression suppressed the proteasome activity in HepG2 cells. Such effect is comparable to, but not additive with, siRNA-mediated silence of Nrf1, a well-known proteasome regulator that coordinately induces proteasome gene transcription. This implies that NDRG2 exerts its role by inhibiting Nrf1. Finally, we demonstrated that NDRG2 interacts with Nrf1 and promotes its downregulation. Conclusion: We demonstrated for the first time that NDRG2 is a critical regulator of lipid metabolism and proteasome activity. NDRG2 inhibits the proteasome activity probably by interacting with Nrf1 and promoting its downregulation. Note: This abstract was not presented at the conference. Citation Format: Libo Yao, Xia Li, Xiping Liu, Yi Ru, Mei Zhang. N-Myc downstream regulated gene 2 is a novel regulator of lipid metabolism and ubiquitin-proteasome system in cancer. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr B05.
Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV
Authors: Benjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, Susanne Saussele, Philipp Erben, Christian Dietz, Alice Fabarius, Ulrike Proetel, Lida Kalmanti, Susanne Schnittger, Stefan W. Krause, Jörg Schubert, Hermann Einsele, Mathias Hänel, Jolanta Dengler, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Gabriela M. Baerlocher, Markus Pfirrmann, Joerg Hasford, Wolf-Karsten Hofmann, Andreas Hochhaus, Martin C. Müller
Journal: Blood (2014)
Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study
Authors: Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Yohei Shimono, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
Journal: Blood (2014)
N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)
Authors: Paolo Milani, Morie A. Gertz, Giampaolo Merlini, Giovanni Palladini, Martha Q. Lacy, Francis K. Baudi, Shaji K. Kumar, Suzanne R. Hayman, Nelson Leung, David Dingli, John A. Lust, Yi Lin, Prashant Kapoor, Ronald S. Go, Steven R. Zeldenrust, Yi L. Hwa, Robert A. Kyle, S. Vincent Rajkumar, Angela Dispenzieri
Journal: Blood (2015)
Autologous Hematopoietic Progenitor Cell Infusion Adverse Event Associated with Apheresis Product Granulocyte Content
Authors: Araci M. Sakashita, Andrea Tiemi Kondo, Ana Paula Hitomi Yokoyama, Carolina Bonet Bub, Sanny Marcele da Costa Lira, Cristiane Yoshie Nakazawa, Andrea Neri Folchini Cipolletta, Nelson Hamerschlak, Jose M Kutner
Journal: Blood (2015)
Pro and con: Internal speech and the evolution of complex language
Authors: Christina Behme
Journal: Behavioral and Brain Sciences (2016)

Abstract The target article by Christiansen &amp; Chater (C&amp;C) offers an integrated framework for the study of language acquisition and, possibly, a novel role for internal speech in language acquisition. However, the “Now-or-Never bottleneck” raises a paradox for language evolution. It seems to imply that language complexity has been either reduced over time or has remained the same. How, then, could languages as complex as ours have evolved in prelinguistic ancestors? Linguistic Platonism could offer a solution to this paradox.
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia
Authors: Maria Chiara Fontana, Viviana Guadagnuolo, Cristina Papayannidis, Giorgia Simonetti, Antonella Padella, Anna Ferrari, Marco Manfrini, Italo Faria do Valle, Barbara Santacroce, Margherita Perricone, Giovanni Marconi, Emanuela Ottaviani, Jelena D. Milosevic Feenstra, Doris Chen, Nicole C.C. Them, Simona Soverini, Daniel Remondini, Gerardo Musuraca, Michele Cavo, Robert Kralovics, Giovanni Martinelli
Journal: Blood (2015)
The Application of Genomics in Diabetes: Barriers to Discovery and Implementation
Authors: James S. Floyd, Bruce M. Psaty
Journal: Diabetes Care (2016)

The emerging availability of genomic and electronic health data in large populations is a powerful tool for research that has drawn interest in bringing precision medicine to diabetes. In this article, we discuss the potential application of genomics to the prediction, prevention, and treatment of diabetes, and we use examples from other areas of medicine to illustrate some of the challenges involved in conducting genomics research in human populations and implementing findings in practice. At this time, a major barrier to the application of genomics in diabetes care is the lack of actionable genomic findings. Whether genomic information should be used in clinical practice requires a framework for evaluating the validity and clinical utility of this approach, an improved integration of genomic data into electronic health records, and the clinical decision support and educational resources for clinicians to use these data. Efforts to identify optimal approaches in all of these domains are in progress and may help to bring diabetes into the era of genomic medicine.